Balancing benefits and risks in the era of biologics

Author:

Adami Giovanni1ORCID,Saag Kenneth G.2ORCID,Chapurlat Roland D.3,Guañabens Nuria4,Haugeberg Glenn5,Lems Willem F.6,Matijevic Radmila78,Peel Nicola9,Poddubnyy Denis1011ORCID,Geusens Piet1213

Affiliation:

1. Rheumatology Unit, University of Verona, Pz Scuro 10, 37135, Verona, Italy

2. Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, USA

3. INSERM UMR 1033, Université de Lyon, Hôpital E Herriot, Lyon, France

4. Rheumatology Department, Hospital Clinic, CIBERehd, IDIBAPS, University of Barcelona, Barcelona, Spain

5. Division of Rheumatology, Medicine Department, Southern Hospital Trust, Trondheim, Norway

6. Amsterdam UMC, location VUmc, Amsterdam, the Netherlands

7. University of Novi Sad, Faculty of Medicine, Novi Sad, Serbia

8. Clinical Center of Vojvodina, Clinic for Orthopedic Surgery, Novi Sad, Serbia

9. Metabolic Bone Centre, Northern General Hospital Sheffield, UK

10. Department of Gastroenterology, Infectious Diseases, and Rheumatology, Charité - Universitätsmedizin Berlin, Berlin, Germany

11. Epidemiology Unit, German Rheumatism Research Centre, Berlin, Germany

12. CAPHRI School for Public Health and Primary Care, Maastricht University, Maastricht, the Netherlands

13. Biomedical Research Center, Hasselt University, Agoralaan, Gebouw D, Diepenbeek, Belgium

Abstract

Biologics are substances synthetized from biological sources used in the prevention and treatment of several diseases. Rheumatologists have many years of experience with biologics for the treatment of immune-mediated diseases and osteoporosis. Randomized clinical trials and postmarketing studies have demonstrated that treatment with biologics can result, albeit infrequently, in serious adverse events. To date, several risk mitigation strategies have been identified and implemented. The objective of the present perspective review is to examine the risk mitigation strategies of biologic treatments, with special focus on anti-tumor necrosis factors and denosumab.

Publisher

SAGE Publications

Subject

Orthopedics and Sports Medicine,Rheumatology

Cited by 14 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3